Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

Abstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antig...

Full description

Bibliographic Details
Main Authors: Luca Foroghi Biland, Ludovica Ferrari, Vincenzo Malagnino, Elisabetta Teti, Carlotta Cerva, Adele Gentile, Marianna Aragri, Romina Salpini, Valentina Svicher, Massimo Andreoni, Loredana Sarmati
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Journal of Medical Case Reports
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13256-019-2232-3
id doaj-6c31c32ac95f46bfa8d17d97eee37d5b
record_format Article
spelling doaj-6c31c32ac95f46bfa8d17d97eee37d5b2020-11-25T03:01:50ZengBMCJournal of Medical Case Reports1752-19472019-09-011311510.1186/s13256-019-2232-3Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case reportLuca Foroghi Biland0Ludovica Ferrari1Vincenzo Malagnino2Elisabetta Teti3Carlotta Cerva4Adele Gentile5Marianna Aragri6Romina Salpini7Valentina Svicher8Massimo Andreoni9Loredana Sarmati10Infectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataDepartment of Experimental Medicine and Surgery, University of Rome Tor VergataDepartment of Experimental Medicine and Surgery, University of Rome Tor VergataDepartment of Experimental Medicine and Surgery, University of Rome Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataInfectious Diseases Clinic, Policlinico Tor VergataAbstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. Case presentation We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region. Conclusions We speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.http://link.springer.com/article/10.1186/s13256-019-2232-3Hepatitis B virusHBV reactivationDirect acting antiviralsCoinfection HBV/HCVImmune-escape HBV mutant
collection DOAJ
language English
format Article
sources DOAJ
author Luca Foroghi Biland
Ludovica Ferrari
Vincenzo Malagnino
Elisabetta Teti
Carlotta Cerva
Adele Gentile
Marianna Aragri
Romina Salpini
Valentina Svicher
Massimo Andreoni
Loredana Sarmati
spellingShingle Luca Foroghi Biland
Ludovica Ferrari
Vincenzo Malagnino
Elisabetta Teti
Carlotta Cerva
Adele Gentile
Marianna Aragri
Romina Salpini
Valentina Svicher
Massimo Andreoni
Loredana Sarmati
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
Journal of Medical Case Reports
Hepatitis B virus
HBV reactivation
Direct acting antivirals
Coinfection HBV/HCV
Immune-escape HBV mutant
author_facet Luca Foroghi Biland
Ludovica Ferrari
Vincenzo Malagnino
Elisabetta Teti
Carlotta Cerva
Adele Gentile
Marianna Aragri
Romina Salpini
Valentina Svicher
Massimo Andreoni
Loredana Sarmati
author_sort Luca Foroghi Biland
title Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
title_short Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
title_full Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
title_fullStr Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
title_full_unstemmed Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
title_sort hepatitis b virus reactivation sustained by a hepatitis b virus surface antigen immune-escape mutant isolate in a patient who was hepatitis b core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis c virus infection: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2019-09-01
description Abstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. Case presentation We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region. Conclusions We speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.
topic Hepatitis B virus
HBV reactivation
Direct acting antivirals
Coinfection HBV/HCV
Immune-escape HBV mutant
url http://link.springer.com/article/10.1186/s13256-019-2232-3
work_keys_str_mv AT lucaforoghibiland hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT ludovicaferrari hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT vincenzomalagnino hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT elisabettateti hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT carlottacerva hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT adelegentile hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT mariannaaragri hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT rominasalpini hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT valentinasvicher hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT massimoandreoni hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
AT loredanasarmati hepatitisbvirusreactivationsustainedbyahepatitisbvirussurfaceantigenimmuneescapemutantisolateinapatientwhowashepatitisbcoreantibodypositiveduringtreatmentwithsofosbuvirandvelpatasvirforhepatitiscvirusinfectionacasereport
_version_ 1724691712752746496